We are thrilled to announce that OPTIC, an innovative AI-powered drug discovery platform, has successfully raised $11 million in its latest funding round. This significant investment underscores the confidence in our mission to revolutionize the biotech industry through rapid molecule screening and testing. With advanced capabilities ranging from target identification to lab validation, our platform automates crucial biotech R&D processes, drastically reducing the time and resources needed to bring new drugs to market. Originally founded as an AI research team focused on high-performance similarity search algorithms, OPTIC has evolved to deploy its proprietary AI technology across various sectors, including blockchain and biotech. The funding will be instrumental in further enhancing our technology and expanding our capabilities to meet the demands of a fast-changing healthcare landscape. We are committed to driving innovation and improving the efficiency of drug discovery, thereby enabling researchers and pharmaceutical companies to accelerate their development timelines and bring essential treatments to patients sooner. As we embark on this exciting new chapter, we thank our investors for their belief in OPTIC's vision and look forward to transforming the future of drug development together.
Breaking News: OPTIC Secures $11M in Seed Funding for AI-Powered Drug Discovery Platform
Recently funded 路 $11.0M SeedPharmaceuticals
Get the full OPTIC company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Aisot Technologies Switzerland | Seed | $2.5M | today |
| 2 |  DIMENSION United States | Seed | $1.6M | today |
